Fortress Biotech (FBIO)
Sources, funds and advances drug assets through a portfolio-company network.
Something off on this page? Send us feedback.
Sources, funds and advances biopharmaceutical assets through Fortress, controlled subsidiaries and partner companies. Monetization comes from product revenue and portfolio interests, including equity, dividends and royalties.
Sources, funds and advances biopharmaceutical assets through its own operations, controlled subsidiaries and partner companies. Product revenue and interests in portfolio companies, including equity, dividends and royalties, form the routes to monetization.
Works with academic, research and pharmaceutical institutions to identify and evaluate candidates, then provides funding and management services to development and commercializing companies. This approach connects direct drug development with a portfolio-company structure.
Recent outcomes include subsidiary Checkpoint's acquisition by Sun Pharma and Cyprium's sale of a Priority Review Voucher after FDA approval of ZYCUBO for pediatric Menkes disease. The model depends on portfolio companies progressing assets and on value being realized through product, ownership and royalty interests.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 18, 2026 | Industrial Alliance Securities | Target | Target: — | Target: $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $196.6M · Total debt $64.8M · Total assets $316.7M · Shareholders' equity $164.1M
- Revenue
- $18.7M
- Operating income
- −$10.0M
- Net income
- −$468.0K
No dividends on record.
| Institutions | 17.37% | 5.79M shares | |
|---|---|---|---|
| 60 holders · as of Jun 30, 2026 | |||
| Insiders | 34.76% | 11.59M shares | |
| 9 holders · as of Jun 24, 2026 | |||
| Strategic holders | 13.53% | 4.51M shares | |
| 2 holders · as of Sep 1, 2026 | |||
| Other | 34.34% | 11.45M shares | |
| remainder | |||
33.35M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Lindsay A. Md Rosenwald1Insiderdirector, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN | 20.74% | 6.92M | filed Mar 20, 2026 |
Highbridge Capital Management, LLCStrategic | 8.20% | 2.73M | filed Oct 25, 2024 |
Michael S. WeissInsiderdirector, officer: Executive Vice Chairman | 6.83% | 2.28M | filed Mar 20, 2026 |
Integrated Core Strategies (US) LLCStrategic | 5.33% | 1.78M | filed Sep 1, 2026 |
David JinInsiderofficer: Chief Financial Officer | 4.95% | 1.65M | filed Jun 24, 2026 |
- Lindsay A. Md Rosenwald's transaction reports restate only vehicles that traded; the 2026 ownership statement (6.92M) is used instead.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Bausch Health
Prescription acne rival with U.S. products including CABTREO and Arazlo
- Almonty Industries
Seysara overlaps directly in U.S. moderate-to-severe inflammatory acne
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Fortress Biotech | $2.44 | +1.04% | $80.1M | 0.9 | — | 1.2 | +14.0% |
| Bausch Health | $5.76 | +2.04% | $2.11B | — | 1.3 | 0.2 | +11.2% |
| Almonty Industries | $14.34 | −2.18% | $4.16B | — | 15.5 | — | +484.5% |
| Median | — | 8.4 | 0.2 | +247.9% |